New drug aims to ease sickle cell burden by boosting protective protein
NCT ID NCT06546670
Summary
This early-stage study is testing a new drug called ITU512 for sickle cell disease. The main goal is to see if it's safe and how it works in the body, particularly its ability to increase a protective type of hemoglobin that can reduce sickling of red blood cells. The study will first involve healthy volunteers and then patients with sickle cell disease to gather initial evidence of its potential benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Quotient Sciences Sea View
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.